LoginSign Up
My AccountLogout
Smart Today

Search results for "EU"

Samba Signs 1.1 Trillion Won Pharmaceutical Production Contract with European Pharmaceutical Company.. Acquisition of Local Production Plant in the U.S.

Samba Signs 1.1 Trillion Won Pharmaceutical Production Contract with European Pharmaceutical Company.. Acquisition of Local Production Plant in the U.S.

|Smart Today=Reporter Kim Se-hyung| Samsung Biologics announced on the 22nd that it signed a contract for consignment...
김세형 기자 ·
Korea Exchange, Revamps ESG Portal.. Launches English Service

Korea Exchange, Revamps ESG Portal.. Launches English Service

Korea Exchange (Chairman Jeong Eun-bo) announced on the 29th that it will improve the ESG comprehensive information...
김세형 기자 ·
[Table] Korea Investment Trust Management ACE Monthly Dividend ETF December Distribution Details

Table Korea Investment Trust Management ACE Monthly Dividend ETF December Distribution Details

Korea Investment Trust Management announced the December distribution details for the monthly dividend products among...
김세형 기자 ·
Chairman Chung Ki-sun,

Chairman Chung Ki-sun, "HD Hyundai's strengths are execution and drive, while also creating a culture of communication"

|Smart Today=Reporter Na Gi-cheon| Chairman Chung Ki-sun of HD Hyundai is intensifying his leadership centered on...
나기천 기자 ·
Samsung C&T Wins 2 Trillion Won 'CO2 Transfer Facility' Construction Order in Qatar

Samsung C&T Wins 2 Trillion Won 'CO2 Transfer Facility' Construction Order in Qatar

Samsung C&T has successfully secured a large-scale eco-friendly energy facility project worth over 2 trillion won in...
이재수 기자 ·
Games, Benefiting from King Dollar.. W Games to See the Largest Benefit - Hana

Games, Benefiting from King Dollar.. W Games to See the Largest Benefit - Hana

|Smart Today=Reporter Kim Se-hyung| Hana Securities stated on the 22nd that game companies with a high proportion of...
김세형 기자 ·
Year-End Financial Holding Subsidiary Personnel Changes Converge on 'Stability'

Year-End Financial Holding Subsidiary Personnel Changes Converge on 'Stability'

The common keyword for the year-end CEO appointments of financial holding subsidiaries has been gathered as 'stability.
강민주 기자 ·

Most Viewed

1

Lee Chan-won, Model for Dong-A Pharmaceutical's Cold Medicine Panpyrin

 2

Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion

 3

Samsung Electronics, Target Price of 200,000 Won Emerges.. Equivalent to 10 Million Won Before Stock Split

 4

Samsung Electronics Reports 20 Trillion Won Operating Profit in Q4, Exceeding Heightened Expectations

 5

KOSPI Breaks 4500.. Rally for Three Consecutive Days in the New Year

Picks for You

Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion

Samsung Electronics, Target Price of 200,000 Won Emerges.. Equivalent to 10 Million Won Before Stock Split

KOSPI Breaks 4500.. Rally for Three Consecutive Days in the New Year

Stock Market Receives the Energy of the Red Horse.. First Day Breaks 4300 for the First Time

Samba Signs 1.1 Trillion Won Pharmaceutical Production Contract with European Pharmaceutical Company.. Acquisition of Local Production Plant in the U.S.

Youngpoong·MBK Partners "Korea Zinc, Choi Yoon-bum Takes on High Risks to Secure Management Rights"

Photos & Videos

Lee Chan-won, Model for Dong-A Pharmaceutical's Cold Medicine Panpyrin

Lee Chan-won, Model for Dong-A Pharmaceutical's Cold Medicine Panpyrin
Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion

Samsung Biologics Surpasses Annual Revenue of 4.5 Trillion Won... Operating Profit of 2 Trillion
Samsung Electronics, Target Price of 200,000 Won Emerges.. Equivalent to 10 Million Won Before Stock Split

Samsung Electronics, Target Price of 200,000 Won Emerges.. Equivalent to 10 Million Won Before Stock Split
Samsung Electronics Reports 20 Trillion Won Operating Profit in Q4, Exceeding Heightened Expectations

Samsung Electronics Reports 20 Trillion Won Operating Profit in Q4, Exceeding Heightened Expectations